MTOR and tuberous sclerosis: Transgenic mouse models of tuberous sclerosis such as Tsc2+/− and Tsc1+/− exhibit increased activity in the mTOR pathway, which is accompanied by deficits in long-term potentiation and spatial learning, which can be reversed by chronic treatment with a rapamycin, a mTOR pathway inhibitor [25].